Last reviewed · How we verify
NCT04732208
Automated Screening of Diabetic Retinopathy Using a Smartphone-based Camera
trial testing Colour fundus photography in Diabetic Retinopathy in 410 participants. Completed in 24 August 2022.
24 August 2022
Quick facts
| Lead sponsor | Tameside General Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 410 |
| Start date | 20 April 2022 |
| Primary completion | 24 August 2022 |
| Estimated completion | 24 August 2022 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Colour fundus photography
Conditions studied
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
Sponsor
Tameside General Hospital
Who can join
18 and older, any sex, with Diabetic Retinopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The prevalence of diabetic retinopathy (DR) in the UK is on the rise. Within 20 years of diabetes diagnosis, nearly all people with type 1 and almost two thirds of people with type 2 diabetes (60%) have some degree of DR. NHS guidelines mandate annual DR screening in all patients aged 12 and above to prevent complications of DR. Screening for DR in England involves labour-intensive manual grading of retinal images through the teleophthalmology platform. Automated retinal image analysis systems with the use of artificial intelligence (AI) may offer an alternative to manual grading. The purpose of this study is to evaluate the performance of a portable, hand-held fundus camera with integrated artificial intelligence for diabetic retinopathy screening by comparing it against the current standard i.e diagnosis provided by trained human graders evaluating the standard photographs/ophthalmologists.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04732208
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Retinopathy
Currently open trials in the same condition.
- NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes · NA · recruiting
- NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06713720 — Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy · NA · recruiting
- NCT06892353 — AI-Powered DIY Screening System for Diabetic Retinopathy · NA · recruiting
Other Tameside General Hospital trials
Trials by the same sponsor.
- NCT06695325 — Convenient Home Access for Routine Monitoring in Diabetes (Charm-D Study) · recruiting
- NCT04653545 — Diabetes Diagnosis During Acute Admissions (FIND-IT) · completed
- NCT04386044 — Investigating the Role of Vitamin D in the Morbidity of COVID-19 Patients · completed
- NCT05240196 — Binaural Music Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04732208 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tameside General Hospital
- Last refreshed: 2 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04732208.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing